Blue Cross and Blue Shield of Illinois policy

Gene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa

Gene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa is a public Blue Cross and Blue Shield of Illinois policy (policy RX501.164, effective Jun 15, 2026). It lists 2 CPT or HCPCS codes. Not a coverage decision; the payer's own document governs.

View the original policy (PDF) ↗

Payer: Blue Cross and Blue Shield of Illinois
Policy number: RX501.164
Effective: Jun 15, 2026
Line of business: Commercial, Medicaid
Source: medicalpolicy.hcsc.com

Codes in this policy

The CPT and HCPCS codes the policy names. A policy can name a code it excludes.

Code	Other Blue Cross and Blue Shield of Illinois policies
J3389	Policies naming J3389
J3401	Policies naming J3401

All Blue Cross and Blue Shield of Illinois policies

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.